



LYONBIOPOLE
AUVERGNE-RHÔNE-ALPES



La Région
Auvergne-Rhône-Alpes

AUVERGNE RHÔNE-ALPES DELEGATION



French Pavilion
Booth#951



BIO International
Convention
The Global Event for Biotechnology

June 5-8, 2023
Boston, MA

DISCOVER A MAJOR HEALTHTECH ECOSYSTEM

TABLE OF CONTENTS

1st health manufacturing region in France

1st region in France for bioproduction

1st region in France for R&D

900 innovative players



CO-EXHIBITING COMPANIES

3-D MATRIX EUROPE	4	KARLA THERAPEUTICS	17
ABL	5	CENTRE LEON BERARD	18
AMOLYT PHARMA	6	LYS THERAPEUTICS	19
ANS BIOTECH S.A.	7	NETRIS PHARMA	20
AXOLTIS PHARMA	8	NOVADISCOVERY	21
CAPEVAL PHARMA	9	ROOWIN	22
CYNBIOSE	10	SEQENS	23
DEEPLINK MEDICAL	11	SIGNIA THERAPEUTICS	24
ERYTECH PHARMA	12	SKYEPHARMA PRODUCTION	25
FABENTECH	13	THERANEXUS	26
GAOMA THERAPEUTICS	14	TRANSCURE BIOSERVICES	27
GENCOVERY	15	VIDIUM	28
INOVOTION	16		

PARTNERS

AUVERGNE-RHÔNE-ALPES	30
ONLYLYON	31
LYONBIOPOLE	32



3-D Matrix is a medical device company built around self-assembling peptide technology platform originally developed at MIT. Our flagship product is PuraStat, a CE marked, FDA cleared product used for bleeding management. Our R&D is also focused on the areas of tissue regeneration and drug delivery.

PuraStat was approved recently under the new European MDR regulation. In the US, PuraStat received a new 510k clearance for treatment of primary bleeding.

Contact: **Vincent MORTUREUX - EU R&D Manager**
E-mail: vmortureux@puramatrix.com

11, chemin des petites brosses
F - 69300 CALUIRE ET CUIRE
www.3dmatrix.com



A subsidiary of Institut Mérieux, ABL is a pure play CDMO whose mission is to provide GMP viral vectors and vaccines from early stage to market through the development and manufacturing of bulk drug substance and drug product, including QC testing and regulatory support.

ABL is developing an in-house, versatile AAV platform in suspension, enabling the manufacturing of a broad range of serotypes and has entered into a strategic partnership with RD-Biotech - an expert in the development and manufacturing of plasmids - to provide a one-stop-shop offering from gene to viral vector DP to its customers.

Contact: **Thierry VAN NIEUWENHOVE - CEO**
E-mail: thierry.vannieuwenhove@ablinc.com

261 rue Marcel Mérieux
F - 69007 LYON
www.abl-biomanufacturing.com



Amolyt Pharma, a clinical stage biotechnology company, is building on its team's established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors.

January 6, 2023: Closing of a €130 million (approx. \$138M) Series C equity financing.

May 2, 2023: Amolyt Pharma Announces Phase 3 Clinical Trial of Eneboparatide for the Treatment of Hypoparathyroidism following Positive End of Phase 2 Meeting with FDA.

Contact: **Thierry ABRIBAT - Founder and Chief Executive Officer**

E-mail: tabribat@amolyt.com

15 chemin du saquin
F - 69289 ECULLY

www.amolytpharma.com



ANS Biotech is a French CRO dedicated to the pharmacology of pain. As a close Pharma and Biotech partner, ANS Biotech helps its Clients to evaluate the efficacy of their candidates using behavioral preclinical models in various pain areas in compliance with the highest ethical and quality standards.

Contact: **Yassine DARBAKY - Chief Business Officer**

E-mail: yassine.darbaky@ans-biotech.com

20-22 rue Henri & Gilberte Goudier
F - 63200 RIOM

www.ans-biotech.com



AXOLTIS Pharma, The CNS Regeneration Company[®], is a France based biotech company. Its product, NX210c, is currently in a phase Ib clinical study to confirm its good safety profile and pharmacological effects. The company is looking for a partner and/or investors to accelerate in the development.

The company is looking for fundraising and/or partnering to pursue the drug development up to phase II clinical trials in (rare) neurological diseases.

Contact: **Dr Yann GODFRIN - CEO**
E-mail: ygodfrin@axoltis.com

60, av. Rockefeller
F - 69008 LYON

www.axoltis.com



30-year NCD/toxicology consulting, due diligence, ocular, cardiovasc, fundraising, partnerships. NCD plan, CRO selection, monitoring, reporting & submission to regulatory authorities (mainly EU/US). Global dvpt strategy In/outlicensing/partnership Due Dil support (startup, big pharma, investors).

AFSSI board, Roca therapeutics board, president International Society of Ocular Toxicology, Member of Orientation and Training Council for Veterinary Ophthalmology, President CEEAG Geneva.

Contact: **Olivier LOGET - President and CEO**
E-mail: olivier.loget@capeval-pharma.com

Archamps Technopole Le Forum 2 - 218, av. Marie Curie
F - 74160 ARCHAMPS

www.capeval-pharma.com



Cynbiose is a unique European non-clinical CRO specialized in the NHP model. Our services ranges from non-GLP DMPK, early safety studies to PoC studies (respiratory infectious diseases & CNS). Our state-of-the-art facility is AAALAC-accredited and can operate studies in BSL1- 3 as well as GMOs C1-2.

Cynbiose contributed to the non-clinical assessment of HIPRA's Covid-19 Bimervax® vaccine launched on the European market in 2023.

Contact: **Cécile DURAND** - Business development & marketing director
E-mail: cecile.durand@cynbiose.com

8, chemin du Clapeloup
F - 69280 SAINTE CONSORCE
www.cynbiose.com



Created in 2014 by 5 radiologists, Deeplink Medical digitalizes medical imaging with innovative online platforms to optimize patients care, both in clinical trials and routine conditions.

At the beginning of 2023, Deeplink Medical raised €10 million from main French healthcare players to give the oncology and radiology world the ability to influence its future.

Contact: **Hugues LAJOIE** - CEO
E-mail: h.lajoie@deeplink-medical.com

22, rue Seguin
F - 69002 LYON
www.deeplink-medical.com



ERYTECH is a biopharmaceutical company developing red blood cell-based therapeutics. Leveraging two proprietary platforms, ERYCAPS, and ERYCEV, to encapsulate drug substances inside red blood cells and extracellular vesicles, ERYTECH develops candidates for patients with high unmet medical needs.

ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies.

Contact: **Eric SOYER - COO**
E-mail: eric.soyer@erytech.com

Bâtiment Adénine
F - 69008 LYON
www.erytech.com

FABENTECH
Specific Polyclonal Antibodies

Fabentech is a pharmaceutical-stage biotechnology company, specialized in developing, producing and commercialising polyclonal antibodies treatments to cope with emerging infectious diseases and bioterrorism agents in emergency situations.

Fabentech develops life-saving solutions neutralizing viruses and toxins. Its technology platform is proven and validated. Fabentech has 4 ongoing programs, including 2 bioterrorism toxins funded by the French Ministry of Defense and the European Defense Fund. Fabentech is also developing treatments for Nipah virus and COVID-19, with the latter in phase 2 clinical trials.

Contact: **Grégory VERNIER - Head of Business Development**
E-mail: gregory.vernier@fabentech.com

24, rue Jean Baldassini
F - 69007 LYON
www.fabentech.fr



GAOMA
Therapeutics

GAOMA Therapeutics is developing lipids derivatives as innovative drug candidates for the treatment of neurological and inflammatory disorders. We are moving forward a first-in-class drug candidate, GAO-3-02, for the treatment of epilepsy, with a highly differentiated profile.

Contact: **Vincent MUTEL - CEO**
E-mail: vincent.mutel@gaoma-tx.com

59, bd Pinel
F - 69500 BRON

www.gaoma-tx.com



Gencoverly is specialised in the digitisation of complex R&D projects of biotechs and pharmas (easy-access cloud computing, artificial intelligence, omics data, digital twins of metabolism). Applications of our expertise and technology are discovery, metabolic engineering and bioprocess optimisation.

Laureat R&D Booster 2022.

Contact: **Adama OUATTARA - CEO**
E-mail: douattara@gencoverly.com

47, bd du onze novembre 1918
F - 69100 VILLEURBANNE

www.gencoverly.com

inovotion

WHICH MOLECULE WILL STAND OUT

INOVOTION is a biotech company which offers you a unique in vivo technology dedicated to oncology and immuno-oncology efficacy studies. Our assay uses immunocompetent xenograft chicken embryos, which have tremendous advantages: **Fast, Sensitive, Reliable, Translatable, 3R spirit and Affordable.**

*More than 650 client projects - 25,000 human xenografts per year
- 60 human cancer cell lines - 19 cancer types - Programs with PDX and human biopsies (liquid or solid).*

Contact: **Jean VIALLET - CEO**
E-mail: jean.viallet@inovotion.com
BIOPOLIS - 5, avenue du grand sablon
F - 38700 LA TRONCHE
www.inovotion.com



Karla is a drug development company aiming to lead the growing field of immuno-psychiatry. Our therapeutic approach stems from 10 years of research made at Queen Mary University of London (UK) and aims to deliver the first targeted therapy for the treatment of mental disorders.

Karla gathers an international team (France, Netherlands, UK, USA). The company was co-founded with NLC, an Amsterdam-based venture builder, which provided initial preseed funding (consolidated with additional nondilutive financing). Karla has received prizes from experts of the industry: «Most Innovative Startup» at BioFit, winner of the «Startup Spotlight» pitch contest at BIO Europe Spring... The startup is raising 7M€ to accelerate its drug development program and has already received interest from major VCs and pharma companies.

Contact: **Simon LOIODICE - Co-founder and CEO**
E-mail: simon.loiodice@karla-tx.com
2, rue Michel Renaud
F - 63360 SAINT-BEAUZIRE
www.karla-tx.com



Centre Leon Berard is 1 of the top 3 comprehensive cancer centers in France. We have a strong reputation in Care, Education and Research. We develop innovative diagnostics and therapeutics solutions and partner with cancer expert biotechs and academic centers across the Globe for more than 15 years.

2022 KPIs: 2500 employees - 600 FTEs in research - 2000 patients enrolled in clinical trials - 30000 patients on file - 4 new biotechs installed on site - 150 industrial collaboration agreement signed - 12 patent applications.

Contact: **Loic SEBILEAU** - Head of Technology Transfer & Industrial Partnership
E-mail: Loic.sebileau@lyon.unicancer.fr

28, rue laennec
F - 69008 LYON

www.centreleonberard.fr

Lys Therapeutics is a biotechnology company pioneering a revolutionary approach to treat unmet medical needs in patients suffering from neurovascular or neurodegenerative disorders by targeting blood-brain barrier dysfunction.

Contact: **Manuel BLANC** - CEO & co-founder
E-mail: mblanc@lystherapeutics.com

56, rue Saint-Jean-de-Dieu
F - 69007 LYON

www.lystherapeutics.com



NETRIS Pharma is a clinical stage biopharma developing innovative drugs targeting drug resistance to chemo and immunotherapy in oncology, enrolling 400+ pts in 4 Ph2 clinical trials in Uterine, Pancreas, HCC, H&N and melanoma. The company also targets endometriosis with recent promising data.

The Company inked agreements with MSD to access Pembrolizumab in its Phase 1b/2 trial (RHU/Programme d'Excellence) and with ORANO in radiotherapy. NETRIS Pharma's first-in-class approach is awarded by many institutions (BPI, ANR, INcA, FP7, Eurostar) and more recently by EIC Accelerator from EU.

Contact: **Christophe GUICHARD - CFO**
E-mail: christopheguichard@netrispharma.com
Patrick MEHLEN - CEO
E-mail: patrickmehlen@netrispharma.com

28 rue Laennec
F - 69008 LYON

www.netrispharma.com



DISCOVERY

Novadiscovery is a healthtech company specialized in the simulation of clinical trials with virtual patients (in silico clinical trials). We help biotech and pharma companies bring innovative medicine to the market faster, at lower cost and with greater confidence.

Nominated for Prix Galien in 2022, US office opened, Partnership with top 10 pharma companies (Novartis, Janssen, Takeda, Sanofi, etc.).

Contact: **Julie PITRAT - Executive Director Business Development**
E-mail: julie.pitrat@novadiscovery.com

Pl. Giovanni da Verrazzano
F - 69009 LYON

www.novadiscovery.com



Roowin is a French Contract Research Organization founded in 1998. Our core business is fine chemistry with high value, supporting our customers from early drug discovery process development (small GLP quantities) through medium-scale GMP production (up to 30 kg) with strong CMC capabilities.

Roowin extended its footprint in the USA and opened Roowin Inc. the wholly owned subsidiary of Roowin S.A. in San Diego (CA, USA).

Contact Roowin Inc: **Stephane Richard - CEO**

E-mail: srichard@roowin.com

Contact Roowin S.A: **Patrice ROOL - CEO**

E-mail: patrice.rool@roowin.fr

20 rue Henri et Gilberte Goudier

F - 63200 RIOM

www.roowin.com

OUR SCIENCE FOR YOUR FUTURE

SEQENS is a worldwide leader in the development and production of active ingredients, pharmaceutical intermediates, specialty ingredients and cosmetics & personal care leveraging 24 manufacturing sites, 10 R&D centers and 3,400 employees in 10 countries.

Contact: **Candice DU CHAYLA - Group Communications Director**

E-mail: candice.Duchayla@seqens.com

21, chemin de la sauvegarde

F - 69130 ECULLY

www.seqens.com



Signia Therapeutics, an artificial intelligence-driven pharmatech company whose mission is to accelerate drug discovery against respiratory infections and pathologies.

The company has received funding from the European Union's Horizon 2020 Research and Innovation SME Instrument and the European Innovation Council (EIC) Accelerator grant and from Bpifrance.

Contact: **Christine GUILLEN - Strategic Advisor**
E-mail: christine.guillen@signiatherapeutics.com

317, avenue Jean Jaures
F - 69007 LYON

www.signiatherapeutics.com



Skyepharma is an expert CDMO located in France, FDA approved, specialized in formulating, developing and manufacturing complex oral dosage forms (including modified release, HP API, controlled substances, multilayer tablets, etc..). Early stage, clinical and commercial scale. Skyepharma also offers, through its «Skyehub Bioproduction» model, dedicated clinical and commercial capacity for biotech companies.

Contact: **Laurent RIGAUDEAU - Chief Business Officer**
E-mail: l.rigaudeau@skyepharma.fr

55, rue du montmurier
F - 38070 SAINT QUENTIN FALLAVIER

www.skyepharma.com



Theranexus focuses on the discovery and development of innovative medicines to tackle rare neurological disorders. Our flagship program in the clinic is Batten-1, a treatment for Batten disease (CLN3). Through our discovery platform, we explore neuron/glia interactions and their role in rare neurological disorders.

- *May 2023: Theranexus and Beyond Batten Disease Foundation win together FDA agreement on efficacy endpoints for their single phase 3 pivotal trial planned to start end of this year.*
- *February 2023: THERANEXUS, BBDF and Cardiff University present their novel research on Batten-1 and Batten disease at Worldsymposium 2023*
- *February 2023: AISTROSIGHT: New joint project team between Theranexus, INRIA, Claude Bernard University Lyon 1 and Hospices Civils de Lyon targeting rare neurological diseases."*

Contact: **Julien VEYS - Chief Business Development Officer**
E-mail: julien.veys@theranexus.com

60, avenue Rockefeller
F - 69008 LYON

www.theranexus.com



TransCure bioServices is a top-tier CRO, offering exceptional services and results in fully humanized mouse models for the immune system and liver. Our cutting-edge predictive models are designed for Immuno-Oncology, Inflammatory, and Infectious disease preclinical studies, including Vaccines and Immunization.

Contact: **Ha-Yeon KIM-PENARD - Business Developer**
E-mail: ha-yeon.kim-penard@tcbioservices.com

Archamps Technopole - 260, av. Marie Curie
F - 74160 Archamps

www.transcurebioservices.com



Auvergne-Rhône-Alpes

THE 1ST REGION IN FRANCE FOR THE FUTURE OF MEDICINE



- 1st vaccine manufacturing site in Europe
- 150,000 jobs & 800 SMBs in healthcare
- Major research & higher education centers
- 20,000 students & 3600 researchers
- 5 university hospitals
- 1 international agency for research on cancer
- World Health Organization Academy



More about us



Nouveau centre building of the WHO-IARC, International Center for Research on Cancer, inaugurated in May 2023.



RESEARCH AND INNOVATION IN LYON TO PROMOTE HEALTHY LIVING

As a French and international reference in life sciences and healthcare, the Lyon area combines a first-in-class academic and clinical research, major pharmaceutical companies and a dense network of promising start-ups.



Looking for PARTNERSHIP & DEVELOPMENT in the Lyon region?



Real-estate solutions



Financing & aid



Business & partnerships



Legal & taxation



Human resources



Employee mobility



Communications & networking

We are here to help you !

INVEST IN LYON

Florent Gerbaud

LEAD ADVISOR - ONE HEALTH AND LIFE SCIENCES

florent.gerbaud@investinlyon.com

+33 6 17 81 74 28

LYON METROPOLE

Clémence Labat, PhD

LIFE SCIENCES DIRECTOR

clabat@grandlyon.com

+33 6 68 24 18 38

CCI LYON METROPOLE SAINT-ETIENNE ROANNE

Emilie Da Silva

INTERNATIONAL TRADE ADVISOR HEALTHCARE AND LIFESTYLE SECTORS

e.dasilva@lyon-metropole.cci.fr

+33 7 62 28 44 58

THE HEALTH INNOVATION NETWORK

Lyonbiopole Auvergne-Rhône-Alpes is a French biocluster that connects and promotes healthcare innovation in Auvergne-Rhône-Alpes. Its mission is to support the development of innovative technologies, products, and services to address global healthcare challenges.



+ 270 MEMBERS

- 230 innovative SMEs and start-ups
- 19 major companies
- 21 research centers and university hospitals



INNOVATE IN A DYNAMIC ECOSYSTEM

- Access an outstanding industrial, academic and clinical network
- Access to innovative R&D collaborative projects




BOOST YOUR DEVELOPMENT

- Develop new solutions
- Refine their strategy
- Grow your business
- Access R&D facilities



GET CONNECTED TO OUR COMMUNITY



LYONBIPOLE

AUVERGNE-RHÔNE-ALPES 

Simon GUDIN - PhD

Head of International Affairs


simon.gudin@lyonbiopole.com

T. +33 (0)4 72 76 53 30

Bâtiment EKLA

63 avenue Tony Garnier

F - 69007 Lyon



LYONBIPOLE

AUVERGNE-RHÔNE-ALPES 

FOUNDERS & BOARD MEMBERS



BD



BIOMÉRIEUX



**Boehringer
Ingelheim**



sanofi

BOARD MEMBERS

PUBLIC RESEARCH



Université Claude Bernard  Lyon 1



PUBLIC FOUNDER



La Région
Auvergne-Rhône-Alpes

COMPANIES



Exploring together

erytech 



evotec



FOUNDERS



Liberté
Égalité
Fraternité



La Région
Auvergne-Rhône-Alpes



+ **clermont
auvergne
métropole**



Bâtiment EKLA - 63 avenue Tony Garnier, 69007 Lyon

T : +33 (0)4 72 76 53 30 - F : +33 (0)9 55 91 30 26

info@lyonbiopole.com - www.lyonbiopole.com